Table 4.

Association between IL12B polymorphisms and severe disease outcomes.

Genotype	Severe malaria			Hyperparasitaemia (≥250,000/µL)
	Odds ratio	95% CI	p-value	Odds ratio	95% CI	p-value
IL12Bpro (rs17860508)
2.2 (n=65)	reference			reference
1.2 (n=257)	1.04	0.55–1.94	0.910	0.77	0.33–1.80	0.541
1.1 (n=31)	2.34	0.94–5.81	0.066	3.42	1.17–9.97	0.025
IL112B 3’ UTR (T/G)(rs3212227)
TT (n=90)	reference			reference
TG (n=138)	0.61	0.33–1.00	0.096	0.80	0.35–1.79	0.583
GG (n=81)	0.70	0.36–1.39	0.311	0.99	0.40–2.46	0.983

Patients with P. falciparum infection were categorized according to WHO criteria (WHO, 2000) for severe malaria. Patients with severe malaria were also categorized as hyperparasitaemia (≥250,000 parasites/µL) vs. non- hyperparasitaemia (<250,000 parasites/µL). Multivariate logistic regression analyses were performed, controlling for the confounding effects of age and gender. Results are presented as odds ratio (OR) and 95% confidence interval (CI), with p≤0.05 considered statistically significant.